Acadia Pharmaceuticals (NASDAQ:ACAD) recently announced full enrollment in the latest phase 3 clinical trial for it's lead drug candidate Pimavanserin for treatment of Parkinson's disease psychosis (PDP). Based on past movements in the …
The stock’s 52-week high is $48.62. Volume totaled around 15.2 million, about 20% above the daily average. The company had no specific news. Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) traded down about 20% Wednesday to post a …
Shares of major biotech companies stumbled Friday on concerns the sector may be overheated. The iShares NASDAQ …
A 1-for-20 reverse stock split was implemented on January 26, 2018. Clinical Trials & Near-term Catalysts: The lead drug candidate is M207 for the treatment of migraine. A long-term safety study of M207 is underway. -- The Company …
SAN DIEGO (AP) — Acadia Pharmaceuticals Inc. (ACAD) on Friday reported a loss of $54.3 million ... Acadia shares have decreased 47 percent since the beginning of the year. The stock has fallen 51 percent in the last 12 months.
In several ways, Acadia Pharmaceuticals (NASDAQ: ACAD) crushed it in 2017 ... Despite all of this good news, Acadia stock finished the year up only 4%. Acadia CEO Stephen Davis didn't mention the underwhelming performance of the …
All four are rated Buy at Merrill Lynch. This stock got tagged recently, offering investors a very solid entry point. ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company based in San Diego and focused on the …
The 2012 SandHills Stock Show & Rodeo Director Angie Bryant, President Bill Wight and Vice President Kevin Evans presented scholarships to the 2012 Miss Rodeo SandHills Ashley Buffington, Miss Rodeo SandHills Teen Carlie Porter …